DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20195165

Posterior reversible encephalopathy syndrome in cancer patients: experience from a tertiary cancer center, South India

Veerendra Angadi, Manjunath Nandennavar, Shashidhar V. Karpurmath, Roshan Jacob

Abstract


Posterior Reversible Encephalopathy Syndrome (PRES) is characterized by seizures, headaches, altered mental status, cortical blindness and typical transient lesions on MRI. PRES may be associated with chemotherapy, molecular targeted drugs and immunosuppressive agents used in patients with cancer. PRES is a very rare condition in cancer patients. PRES is usually reversible with appropriate supportive care and most patients can be restarted with treatment.


Keywords


Cancer, Chemotherapy, Immunosuppressive agents, Posterior reversible encephalopathy syndrome

Full Text:

PDF

References


McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, Santa Cruz KS, et al. Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. Am J Roentgenol. 2007 Oct;189(4):904-12.

Kim SJ, Im SA, Lee JW, Chung NG, Cho B, Kim HK, et al. Predisposing factors of posterior reversible encephalopathy syndrome in acute childhood leukemia. Pediatr Neurol. 2012 Dec 1;47(6):436-42.

Lucchini G, Grioni D, Colombini A, Contri M, De Grandi C, Rovelli A, et al. Encephalopathy syndrome in children with hemato‐oncological disorders is not always posterior and reversible. Pediatr Blood Cancer. 2008 Nov;51(5):629-33.

Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. Am J Neuroradiol. 2008 Jun 1;29(6):1043-9.

Tamaki KI, Sadoshima SE, Baumbach GL, Iadecola CO, Reis DJ, Heistad DD. Evidence that disruption of the blood-brain barrier precedes reduction in cerebral blood flow in hypertensive encephalopathy. Hypertension. 1984 Mar;6(2):I75.

Bhatt A, Farooq MU, Majid A, Kassab M. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. Nat Rev Neurol. 2009 Mar;5(3):163.

Chen YH, Huang CH. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine. Clin breast cancer. 2012 Jun 1;12(3):222-5.

Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. New Eng J Medi. 2006 Mar 2;354(9):980.

Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep 1;14(9):914-25.

Cacho-Díaz B, Nydia A, Mendoza L, Moreno KS, Soto GR, Rangel CC, Cedillo RC, et al. Chemotherapy-induced posterior reversible encephalopathy syndrome. Medi. 2019;98:19.

Hurwitz RL, Mahoney Jr DH, Armstrong DL, Browder TM. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Medi Pediatr Oncol. 1988;16(3):216-9.

Singer S, Grommes C, Reiner AS, Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist. 2015;20:806-11.

Tang JH, Tian JM, Sheng M, Hu SY, Li Y, Zhang LY, et al. Study of posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia after induction chemotherapy. J Child Neurol. 2016 Mar;31(3):279-84.

Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015 Sep 1;14(9):914-25.